Evaluation of the efficacy and safety of hydroxychloroquine in comparison with chloroquine in moderate and severe patients with COVID-19

作     者：Qiuyu Li Cheng Cui Fei Xu Jianping Zhao Nan Li Haichao Li Tianbing Wang Hua Zhang Na Liu Yudong Wei Xiaoye Niu Yan Xu Jianping Dong Xueting Yao Xiaohong Wang Yahong Chen Haiyan Li Chunli Song Jie Qiao Dongyang Liu Ning Shen Qiuyu Li;Cheng Cui;Fei Xu;Jianping Zhao;Nan Li;Haichao Li;Tianbing Wang;Hua Zhang;Na Liu;Yudong Wei;Xiaoye Niu;Yan Xu;Jianping Dong;Xueting Yao;Xiaohong Wang;Yahong Chen;Haiyan Li;Chunli Song;Jie Qiao;Dongyang Liu;Ning Shen

作者机构：Department of Respiratory and Critical Care MedicinePeking University Third HospitalBeijing 100191China Drug Clinical Trial CenterPeking University Third HospitalBeijing 100191China Deparment of Respiratory and Critical Care Medicinethe First Afiliated Hospital of Nanchang UniversirNanchang 300060 China Department of Respiratory and Critical Care MedicineTongi HospitalTongii Medical CollegeHuazhong Universiy of Science and TechnologyWuhan 430030China Research Center of Clinical EpidemiologyPeking University Third HospitalBejing 100191China Department of Respiratory and Critical Care MedicinePeking University First HospitalBeijing 100034China Trauma CenterPeking University People's HospitalBeijing 100044China Beijing Haidian HospitalHaidian Section of Peking University Third HospitalBeijing 100080Chima Deparment of Cardiology Peking University Third HospitalBeijing 100191China Instiute of Medical InnovationPeking University Third HospitalBejing 100191China 

出 版 物：《Science China(Life Sciences)》 (中国科学（生命科学英文版）)

年 卷 期：2021年第64卷第4期

页      面：660-663页

核心收录：

学科分类：0710[理学-生物学] 1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：supported by MOST(Ministry of Science and Technology of the People's Republic of China)foundation for SARS-Co V-2 Research(2020YFC0844500) the“13th Five-Year”National Science and Technology Major Project of China(2017ZX09101001-002-001,2017ZX09304012) Peking University Health Center Foundation for Combating the Pandemic Programs(BMU2020HKYZX011) 

主　　题：acute respiratory patients 

摘      要：Dear Editor,Since December 2019,severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has been rapidly spreading *** and chloroquine are candidates for the treatment of coronavirus disease 2019(COVID-19)owing to its antiviral effect and immunomodulation properties.